PLX

Protalix BioTherapeutics, Inc. (DE)

1.46 USD
+0.03 (+2.10%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Protalix BioTherapeutics, Inc. (DE) stock is down -0.68% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35.29% of the previous 16 February’s closed higher than January.

About Protalix BioTherapeutics, Inc. (DE)

Protalix BioTherapeutics, Inc. focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials.